Tarsus Pharmaceuticals (TARS) Competitors $41.08 +0.63 (+1.56%) As of 02:30 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TARS vs. LEGN, GRFS, TGTX, NUVL, LNTH, TLX, AXSM, AKRO, ADMA, and PCVXShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Legend Biotech (LEGN), Grifols (GRFS), TG Therapeutics (TGTX), Nuvalent (NUVL), Lantheus (LNTH), Telix Pharmaceuticals (TLX), Axsome Therapeutics (AXSM), Akero Therapeutics (AKRO), ADMA Biologics (ADMA), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Tarsus Pharmaceuticals vs. Its Competitors Legend Biotech Grifols TG Therapeutics Nuvalent Lantheus Telix Pharmaceuticals Axsome Therapeutics Akero Therapeutics ADMA Biologics Vaxcyte Tarsus Pharmaceuticals (NASDAQ:TARS) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do insiders & institutionals believe in TARS or LEGN? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has better valuation and earnings, TARS or LEGN? Tarsus Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M9.43-$115.55M-$2.73-15.05Legend Biotech$627.24M10.36-$177.03M-$0.59-59.92 Does the media refer more to TARS or LEGN? In the previous week, Legend Biotech had 6 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 8 mentions for Legend Biotech and 2 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.23 beat Legend Biotech's score of 0.59 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, TARS or LEGN? Tarsus Pharmaceuticals has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500. Is TARS or LEGN more profitable? Legend Biotech has a net margin of -29.95% compared to Tarsus Pharmaceuticals' net margin of -44.91%. Legend Biotech's return on equity of -21.19% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-44.91% -39.72% -25.74% Legend Biotech -29.95%-21.19%-13.47% Do analysts rate TARS or LEGN? Tarsus Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 62.28%. Legend Biotech has a consensus target price of $72.60, indicating a potential upside of 105.37%. Given Legend Biotech's higher possible upside, analysts plainly believe Legend Biotech is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 SummaryLegend Biotech beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TARS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.73B$2.89B$5.49B$9.01BDividend YieldN/A2.64%5.39%4.09%P/E Ratio-15.0521.5627.4320.06Price / Sales9.43281.29398.25108.31Price / CashN/A41.4736.1356.90Price / Book7.007.518.085.67Net Income-$115.55M-$55.05M$3.16B$248.47M7 Day Performance1.86%3.16%2.12%2.90%1 Month Performance-6.45%5.92%4.43%5.75%1 Year Performance42.00%5.82%35.62%21.36% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals2.2255 of 5 stars$41.08+1.6%$66.67+62.3%+46.8%$1.73B$182.95M-15.0550Positive NewsLEGNLegend Biotech3.2607 of 5 stars$35.49+2.5%$76.20+114.7%-19.7%$6.36B$627.24M-60.152,609News CoverageAnalyst ForecastGRFSGrifols4.0476 of 5 stars$9.04+2.0%$10.30+13.9%+40.2%$6.09B$7.81B7.7323,822TGTXTG Therapeutics3.1556 of 5 stars$35.99-2.0%$40.80+13.4%+98.2%$5.83B$329M149.96290NUVLNuvalent3.7478 of 5 stars$76.30-4.2%$119.60+56.7%+10.3%$5.72BN/A-17.3840Analyst UpgradeInsider TradeLNTHLantheus4.4605 of 5 stars$81.86+0.5%$130.50+59.4%+1.4%$5.64B$1.53B23.26700TLXTelix PharmaceuticalsN/A$16.07+0.4%$22.00+36.9%N/A$5.41B$516.72M0.00N/AAnalyst ForecastGap DownAXSMAxsome Therapeutics4.6576 of 5 stars$104.39+1.0%$172.33+65.1%+31.6%$5.09B$385.69M-18.09380Analyst ForecastAnalyst RevisionAKROAkero Therapeutics3.7543 of 5 stars$53.36-5.0%$82.50+54.6%+131.8%$4.48BN/A-27.3630ADMAADMA Biologics4.2109 of 5 stars$18.21+0.3%$27.67+51.9%+59.1%$4.34B$426.45M21.42530PCVXVaxcyte1.7807 of 5 stars$32.51-0.2%$136.50+319.9%-56.3%$4.20BN/A-8.15160News Coverage Related Companies and Tools Related Companies Legend Biotech Alternatives Grifols Alternatives TG Therapeutics Alternatives Nuvalent Alternatives Lantheus Alternatives Telix Pharmaceuticals Alternatives Axsome Therapeutics Alternatives Akero Therapeutics Alternatives ADMA Biologics Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TARS) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
